Psilocybin + Mindfulness Therapy for PTSD

This trial explores how psilocybin, a compound found in certain mushrooms, paired with mindfulness therapy, might help people with PTSD, a condition causing severe stress after trauma. Researchers aim to determine if this combination can improve PTSD symptoms by examining changes in brain activity. Participants will receive either psilocybin with standard support or with added mindfulness-based therapy. The trial seeks individuals diagnosed with moderate to severe PTSD who have maintained a stable dose of antidepressants without major changes for a month. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

You may need to stop certain medications before joining the trial. Specifically, you cannot be on monoamine oxidase inhibitors, tricyclic antidepressants, certain non-SSRI or non-SNRI antidepressants, antipsychotics, mood stabilizers, or psychotropic medicines that interact with psilocybin. However, you can continue a stable dose of SSRI antidepressants or sedatives/hypnotics. The study team will review your medications to ensure safety.

Earlier studies have found psilocybin to be generally safe and well-tolerated when used with psychological support. Research showed that a 25 mg dose did not cause any unexpected side effects, indicating likely safety. Participants also experienced improvements in PTSD symptoms.

Mindfulness-Based Cognitive Therapy (MBCT) is considered a promising method for treating PTSD. Often used alongside other treatments, it has effectively reduced PTSD symptoms.

Unlike the standard treatments for PTSD, which often involve antidepressants or therapy over prolonged periods, the treatment using psilocybin is unique because it offers a novel approach with the potential for rapid and profound effects. Psilocybin, a psychedelic compound, targets serotonin receptors in the brain, which could lead to significant reductions in PTSD symptoms after just a single dose. Researchers are excited about this approach because it combines the mind-altering effects of psilocybin with Mindfulness-Based Cognitive Therapy (MBCT), which may enhance the therapeutic process by fostering greater emotional insight and healing. Additionally, the potential for faster results with fewer doses could revolutionize how PTSD is treated, offering hope for those who haven't found relief with traditional methods.

Research has shown that psilocybin, when combined with psychological support, can significantly reduce PTSD symptoms. For instance, in a study with veterans, 60% of participants showed improvement, and 53% no longer had PTSD symptoms after three weeks. Even after 12 weeks, nearly half maintained their progress. Another study found that psilocybin helped lower PTSD symptoms, attachment anxiety, and feelings of hopelessness in trauma survivors. In this trial, one group of participants will receive psilocybin with psychological support and Mindfulness-Based Cognitive Therapy (MBCT), which might enhance these positive effects. Another group will receive psilocybin with psychological support only. Overall, these findings suggest that psilocybin could be a promising treatment option for those with PTSD.⁶⁷⁸⁹¹⁰